

Durham Research Online

Deposited in DRO:

19 April 2018

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Allen, Susan J. and Dixon, C. Jane and Chazot, Paul L. (2018) 'Can H₂-receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? a case report.', *British journal of clinical pharmacology*, 84 (7). pp. 1611-1616.

Further information on publisher's website:

<https://doi.org/10.1111/bcp.13578>

Publisher's copyright statement:

This is the accepted version of the following article: Allen, Susan J., Dixon, C. Jane Chazot, Paul L. (2018). Can H₂-receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report. *British Journal of Clinical Pharmacology* 84(7): 1611-1616 which has been published in final form at <https://doi.org/10.1111/bcp.13578>. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.

Can H₂-receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19 year old female? A case report

(short running title: 'Anaphylaxis on cessation of ranitidine')

Susan J Allen^{1*}, C Jane Dixon², Paul L Chazot²

1 Susan J Allen MRPharmS PGDip
Senior Lecturer in Pharmacy Practice
Leicester School of Pharmacy
De Montfort University
Hawthorn Building
Leicester LE1 9BH
Paul L Chazot PhD FBPhS
Associate Professor in Pharmacology
2 Department of Biosciences
Durham University
South Road
Durham DH13LE

C Jane Dixon PhD
Senior Lecturer in Pharmacology
Leicester School of Pharmacy
De Montfort University
Hawthorn Building
Leicester LE1 9BH

* Author for correspondence: Susan J Allen, sjallen@dmu.ac.uk

The patient was treated at:

The Minor Injuries Unit, Townlands Memorial Hospital, Henley, Oxon RG9 2DR and transferred for observation to: Royal Berkshire Hospital, Reading, Berks RG1 5AN.

Conflict of interest statement

There are no conflicts of interest with respect any of the authors and the content of this case report.
[The first author, S. Allen, is a relative of the patient subject of this report.]

Ethics

This is a retrospective case report of an unpredicted adverse effect following drug withdrawal.
Informed written consent to obtain hospital results and to publish was obtained from the patient.
Patient identity is protected and confidentiality observed at every stage.

21 **Summary**

22 The anaphylactoid reaction described follows cessation of ranitidine in a 19 year old female with the
23 disease cluster: mast cell activation syndrome, hypermobile Ehlers-Danlos syndrome and postural
24 tachycardia syndrome.

25 Anaphylaxis can give wide-ranging symptoms from rhinorrhoea and urticaria to tachycardia and
26 system-wide, life-threatening, anaphylactic shock. Individuals with a disorder of mast cell activation
27 can experience many such symptoms. H₂ receptor antagonists, such as ranitidine, are commonly
28 prescribed in this population.

29 A mechanism for the reaction is proposed in the context of ranitidine, as an inverse agonist, causing
30 upregulation of H₂ histamine receptors and raised histamine levels due to enzyme induction. This
31 effect, following extended and/or high antihistamine dosing, may have implications for other
32 individuals with a disorder of mast cell activation, such as mastocytosis or mast cell activation
33 syndrome. There are potential policy and patient guidance implications for primary and secondary
34 care with respect to cessation of H₂ antagonists.

35

36 **Key words:** ranitidine, mast cell activation, histamine, upregulation, anaphylaxis

37 **What is already known**

- 38 • Ranitidine, H₂-receptor antagonist (inverse agonist):
 - 39 - can manage symptoms associated with gastric hyperacidity and mast cell activation
 - 40 - has caused: anaphylaxis (rare) upon initiation; intragastric hyperacidity on cessation
- 41 • Sustained H₂ antagonism can: upregulate receptors; alter levels of histamine synthesizing and
42 metabolizing enzymes
- 43 • H₁/H₂ cross-desensitisation has been reported

44

What this paper adds

- Observed anaphylactoid symptoms on stopping ranitidine (in an individual with mast cell activation syndrome)
- A proposed mechanism relating to:
 - upregulation of histamine receptors
 - raised histamine levels due to altered transmitter turnover
 - receptor cross-talk.
- There may be policy implications for cessation of H₂ antagonists

Introduction

Anaphylaxis, a type-1 hypersensitivity response, can be a life-threatening event caused by flooding of mast and basophil cell-derived mediators in response to a stimulus. Drug-induced anaphylaxis has increased in frequency with the advent and administration of a widening array of therapeutic agents. [Ranitidine](#), an [H₂ receptor](#) antagonist, is one such medication which has been reported, albeit rarely, to cause anaphylaxis upon initiation [1]. Although hyperacidity following cessation of ranitidine has been well-documented, to the best of our knowledge, wider histaminergic symptoms have not.

Developed following the pioneering work of Black *et al.* (1972), ranitidine has been widely prescribed since its introduction to the market in 1981 and was a first choice to reduce gastric acid output in gastro-oesophageal reflux disease, functional dyspepsia, and benign gastric or duodenal ulceration [2]. Although its use has been to a large extent superseded by proton pump inhibitors (PPI), such as lansoprazole and omeprazole, it is still widely prescribed and is also available to purchase in lower strength formulations from UK pharmacies and other retail outlets. Individuals with hypermobile Ehlers-Danlos syndrome and/or a disorder of mast cell activation can be prescribed ranitidine to manage gastric symptoms.

The **Ehlers-Danlos syndromes** (EDS) are rare heritable disorders of connective tissues. These syndromes have until recently been classified under the Villefranche Nosology, which described six subtypes of the disorder. In March 2017 the International EDS Consortium proposed a revised classification of thirteen EDS subtypes [3]. Hypermobile EDS (hEDS) is the most common of these subtypes with a prevalence of 1-5 per 10,000 individuals. hEDS is diagnosed by satisfying clinical criteria relating to generalised joint hypermobility, family history, and the presence or absence of signs and symptoms of other connective tissue disorders [3]. Functional gastro-intestinal problems are common and individuals can suffer gastric reflux, nausea, abdominal discomfort and altered gut transit times, leading to both constipation and diarrhoea [4,5].

Disorders associated with **mast cell activation** include mastocytosis and the poorly understood mast cell activation syndrome (MCAS, or idiopathic MCAS). Current proposed MCAS diagnostic criteria are: episodic multisystem symptoms consistent with mast cell activation (which can be due to both IgE- and non-IgE-mediated triggers); appropriate response to medication that targets mast cell activation; documented increases in validated systemic markers of mast cell activation during a symptomatic period compared with the patient's baseline values [6]. However, mast cell activation that is associated with another chronic inflammatory disease does not always meet the diagnostic criteria and can be difficult to diagnose [7,8]. In these patients there is commonly a history of multisystem morbidity of an inflammatory or allergic nature and features of inappropriate mast cell activation, but without evidence of mast cell proliferation [9]. It has further been proposed that lack of raised tryptase, where there is evidence of elevated [histamine](#), suggests involvement of basophils, and that gastric signs and symptoms appear to be more associated with raised histamine than tryptase [10,11]. An association between hEDS, MCAS and postural tachycardia syndrome (PoTS) has been identified [12].

The biogenic amine histamine is synthesized and stored in "professional" basophils and mast cells and released through exocytosis to play a central role in inflammatory or allergic reactions. Four

histamine receptor subtypes have been identified, H₁, H₂, H₃ and H₄; all are G protein-coupled receptors (GPCRs) [13]. Constitutive or spontaneous activity, where a receptor response can be generated in the absence of bound agonist, has been shown for many GPCRs including histamine receptors [14,12]. According to the two-state model for GPCR function, receptors can switch between resting and activated states. Where constitutive activity occurs, a proportion of receptors exists in the active conformation in the absence of bound ligand. Agonists tend to shift the equilibrium towards the active receptor state, while inverse agonists shift it towards the resting state [15,16]. The H₂ receptor ligand ranitidine is known to act as an inverse agonist at the H₂ histamine receptor [17].

Histamine is arguably the most pleiotropic chemical in the human body and its receptors have a wide distribution. H₁ receptors are located in the central nervous system (CNS), smooth muscle, sensory nerves, heart, immune and skin cells, among others [13]. Stimulation of these receptors can give rise to symptoms due to: bronchiolar and gastrointestinal (GI) smooth muscle contraction (causing bronchospasm and difficulty breathing, and diarrhoea respectively); sensory stimulation of the epidermis and dermis (causing itch and pain); vasodilation (causing hypotension, flushing and headache) [16].

H₂ receptors are also widely distributed and found in high concentrations in gastric mucosa, the uterus, CNS, heart and vasculature, respiratory tract, and cells involved in immune function [13,16]. The majority of histamine receptors in the skin are thought to be H₁, with around fifteen percent being H₂ [18]. Stimulation of H₂ receptors promotes hydrochloric acid secretion from gastric parietal cells and can cause symptoms associated with gastric hyperacidity. H₂ receptor stimulation in the cardiovascular system increases heart rate and contractility.

H₃ receptors are highly expressed in the CNS and have a wide distribution elsewhere in the body, including the GI tract, heart, skeletal muscle and sensory nervous system, including in the dermis [13]. Less is known about the most recently discovered H₄ histamine receptor, although mRNA

expression studies have indicated a wide distribution and particular abundance in cells of the immune system, including lymphocytes, monocytes, neutrophils, and eosinophils. H₄ expression has also been demonstrated in the sensory nervous system, skin fibroblasts, GI tract and kidney [13]. Definitive demonstrations of protein and functional expression have, however, yet to be reported [13].

The potentially life-threatening symptoms associated with anaphylaxis are multifaceted and include hypotension, bronchospasm, gastrointestinal symptoms, angio- and laryngeal oedema, cutaneous symptoms and hypothermia [19,20]. These symptoms are induced in susceptible individuals by diverse triggers, including certain foods, insect stings, stress and medication. Such triggers bring about release of the mediators of the pathophysiological effects seen in this serious allergic reaction in which histamine has a central role acting at its receptors located on the affected cells/organs. There is also evidence that histamine influences the activity of a number of inflammatory cell types and is implicated in allergic inflammation via all of the histamine receptors [21], with H₃ and H₄ displaying notable high potency for histamine [13].

Case report

Here we report anaphylactoid symptoms in a white British female aged 19 with co-morbidities of hEDS, MCAS and PoTS, which followed cessation of high-dose ranitidine and culminated in administration of adrenaline.

Medication in the days preceding the anaphylactoid event were: cetirizine tablets 10mg, one at night; Slow Sodium tablets 600mg, 8 daily; paracetamol tablets 500mg, one or two when required, (not taken in the week prior to the event); ondansetron tablets 4mg, one when required (not taken in the week prior to the event); omeprazole tablets 10mg (not taken in the week prior to the event), two at night; and ranitidine 300mg tablets, one twice daily (dose increased from 300mg to 600mg daily, 5 weeks prior to the event).

144 The patient had been advised to stop gastric acid-altering medication in readiness for a gastroscopy
145 and had gradually reduced the dose of omeprazole over a one week period; dosing had stopped 10
146 days prior to the anaphylactoid event. In the three days preceding the event ranitidine was reduced
147 as follows: day 1 - morning dose was omitted and 300mg was taken in the evening; day 2 – morning
148 dose was taken and further dosing stopped. The patient became symptomatic from the evening of
149 day 3 onwards, with symptoms worsening from the morning of day 4.

150 The patient had not experienced anaphylaxis before; the only IgE-mediated allergy she had shown
151 previously was to latex. She had identified a number of food intolerances which caused gastric
152 symptoms, but these symptoms had improved following the addition of H₁ (cetirizine) and increased
153 H₂ (ranitidine) antihistamine medication. She was following a low-FODMAP (fermentable
154 oligosaccharides, disaccharides, monosaccharides and polyols) diet [22] and low histamine diet and
155 had not eaten anything different to normal in the days leading up to the event.

156 **Symptoms leading to administration of adrenaline**

157 On day 3 (described above), the patient experienced abdominal cramps and shivering in the evening
158 and felt cold and dizzy. She woke through the night due to abdominal pain and felt shivery and cold
159 and generally unwell. The abdominal pain continued the following morning and she described
160 feeling shivery, having a running nose and a tight throat, and finding her breakfast hard to swallow.
161 She described looking at her tongue in the mirror because it felt “weird”. She had not experienced
162 these symptoms before. Despite symptoms she went to college but continued to feel cold and
163 noticed a mild red blotchy rash on her arms and felt somewhat itchy all over. Her throat became
164 more bothersome and her chest started to feel tight; at this point she sought medical attention.

165 At the minor injuries unit she was seen immediately. On arrival at 11:07 she was given a 4mg stat
166 dose of oral H₁ antagonist, chlorphenamine. Recorded observations at 11:15 were: temperature
167 36.6°C; pulse 96 beats/min; respiration rate 15 breaths/min; blood pressure 140/87 mmHg; oxygen
168 saturation 99.8%. At 11:35 observations were: pulse 83 beats/min; respiration rate 20 breaths/min,;

blood pressure 143/79 mmHg, oxygen saturation 100%. No flushing, urticaria, stridor or angioedema were observed. At 11:45 the tightness in her chest and throat increased, face flushed, oxygen saturation dropped to 92% and she was administered a stat dose of adrenaline (0.5ml, 1:1000) and oxygen was commenced. Symptoms rapidly abated and she was transferred to the general hospital for observation. She recovered quickly and fully.

Discussion

The case report describes the symptoms experienced by a 19 year old female following cessation of the H₂ receptor antagonist ranitidine. The patient had been prescribed ranitidine to manage gastric symptoms associated with mast cell activation and had taken a 600mg daily dose for 5 weeks prior to the event described here, which coincided with withdrawal of the drug. The 600mg daily dose is at the licensed maximum and is consistent with recommended dosing for prophylaxis and healing of NSAID (non-steroidal anti-inflammatory drugs) -induced duodenal and gastric ulcers, and moderate to severe GORD (gastro-oesophageal reflux disease) [23]. A dose of 300mg daily is, however, more commonly seen in practice.

The early symptoms of shivering, stomach cramps, giddiness (or dizziness, as described by the patient), rhinorrhoea and tongue and throat symptoms experienced by the patient are classic symptoms mediated by histamine, acting at its widely-distributed G protein-coupled receptors.

H₁ and H₂ receptors are co-expressed by many cell types at varying densities, whilst H₃ and H₄ receptors appear to have a more limited distribution [13]. Stimulation of H₁, H₂ and H₃ receptors has been implicated in inducing hypothermia in rodents [20, 24, 25], and abdominal pain and diarrhoea in humans [25]. The patient's subsequent symptoms of chest and throat tightness and flushing are also those of registered anaphylactic reactions attributed to H₁ and H₂ receptor stimulation [27]; a contribution from activated H₃ and H₄ receptors cannot be discounted.

Fullarton and colleagues [28,29] reported the well-documented rebound nocturnal hyperacidity after abrupt withdrawal of a number of H₂ receptor antagonists, including ranitidine. The authors proposed that the underlying mechanism responsible for this phenomenon could be upregulation of parietal cell H₂ receptors. Since then, the concept of constitutive, or spontaneous, activity of many GPCRs has developed, including histamine receptors, in which a proportion of receptors exist in an active state in the absence of agonist [14]. Although almost all of these studies have been conducted in genetically-manipulated systems [reviewed in 13], it is important to note that spontaneous activity of H₃ receptors has been recorded in a native system [30]. It seems likely that the related H₂ receptor also exhibits this behaviour *in vivo*.

In 1996, using a transfected cell model, Smit *et al.* demonstrated that a number of H₂ receptor antagonists, including ranitidine and cimetidine, acted as inverse agonists driving the receptor equilibrium towards the resting state. In doing so these ligands inhibit basal, agonist-independent, activity [17]. The authors described an increase in H₂ receptor density following exposure to ranitidine and cimetidine that was both time- and dose-dependent. This upregulation led to increased basal ligand-independent activity which they suggested might underlie tolerance to these drugs and also contribute to the rebound hyperacidity experienced by patients. Jones *et al.* [31] observed an exaggerated response to a histamine analogue in patients who had been treated for three months with ranitidine at a dose of 150mg at night. They suggested that this observation reflected an increase in receptor number (or upregulation). Upregulation is believed to relate to suppression of H₂ receptor degradation and the recycling of H₂ receptors [32].

Symptoms of rebound hyperacidity have been observed in patients between 24 and 48 hours after the final dose of H₂ antagonist [29,33]. This is consistent with the appearance of the histaminergic symptoms in the case reported here, which began to develop 36 hours from the last dose of ranitidine and became severe at 48 hours. It is tempting to speculate that, in this case, chronic treatment with high dose ranitidine led to H₂ receptor upregulation, giving rise to an increased

217 population of spontaneously active receptors and resulting in H₂ receptor-mediated histaminergic
218 symptoms.

219 It should be noted that the patient involved in this report had been diagnosed with MCAS, where
220 symptoms are experienced as a result of excessive release of pro-inflammatory mediators, including
221 histamine. In such a case, the consequences of ranitidine-induced receptor upregulation could
222 conceivably be magnified, leading to extreme symptoms upon abrupt cessation of ranitidine dosing.

223 An upregulation of H₂ receptors might reasonably account for those symptoms that are obviously
224 mediated by this class of receptor, such as abdominal discomfort. It is less clear how it could account
225 for effects mediated by H₁ (or H₃ or H₄) receptors. It has recently become apparent, however, that
226 cross-talk exists between co-localized H₁ and H₂ receptors, with heterodimers forming and being co-
227 internalized when either receptor is stimulated [34,35]. Once internalized, these receptor dimers
228 may contribute to signalling events and to the overall cellular response. If such events prove to be
229 commonplace, this cross-talk between H₁ and H₂ receptors could explain the appearance of H₁-
230 mediated symptoms, such as rhinorrhoea, that were experienced by this patient.

231 Histamine is synthesized from histidine in a reaction catalysed by histidine decarboxylase (HDC).
232 Monczor and Fernandez [34] described induction of this enzyme by the H₂ receptor antagonist
233 famotidine, resulting in increased levels of histamine, which the authors suggested could contribute
234 to rebound hyperacidity [34]. Such an increase in histamine may be expected to evoke cellular
235 effects mediated by all histamine receptors, and conceivably to an exaggerated response through
236 the up-regulated population of H₂ receptors following antagonist exposure, as seen in this patient.

237 Animal studies have shown that the turnover of histamine varies in different tissues, with resultant
238 differences in histamine half-life (t_{1/2}) of minutes to several days [36]. This variation in histamine
239 turnover has a number of possible explanations in addition to alterations in local tissue HDC. These
240 include receptor-mediated changes in histamine metabolising enzymes (histamine N-methyl

transferase, diamine oxidase), enzyme polymorphisms [37] and differences in histamine uptake activities (deranged histamine turnover). It has also been known for many years that in certain tissues, such as gastric mucosa, H₂ receptor antagonists modulate histamine breakdown by histamine N-methyltransferase [38]. Differences in turnover of histamine in the various tissues affected could account for the timing of symptom onset experienced by the patient.

Taken together, these findings offer a plausible explanation for the symptoms experienced by the patient, which were apparently precipitated by withdrawal of the H₂ receptor antagonist ranitidine. It is proposed that upregulation of H₂ receptors and/or increased levels of histamine underlie these effects. Through cross-talk between H₁ and H₂ receptors, activation of H₁ receptors might also contribute to the full gamut of symptoms experienced by the patient. It is postulated that the severity of symptoms here was a consequence of the sustained duration of high-dose ranitidine, followed by its rapid removal, and the patient's disorder of mast cell activation and hEDS.

Patients with a disorder of mast cell activation (and also gastric symptoms associated with hEDS) can be prescribed both H₁ and H₂ antagonists at elevated doses that are above the manufacturer's guidelines for the drug. This patient was prescribed ranitidine at the maximum dosage and cetirizine at the normal recommended dose. If this reaction had been predicted, increasing the dose of H₁ antagonist prior to ranitidine withdrawal might have reduced the adverse symptoms associated with cessation.

Although hypotension is common in anaphylaxis, patients can also display hypertension which may be a stress response [39]. In the half hour leading up to the administration of adrenaline, two raised systolic readings were recorded in this patient. The effect of anxiety on blood pressure and in promoting further mediator release, thereby exacerbating symptoms in the hospital, cannot be ruled out. In addition, antagonising H₂ receptors has been reported to modify the turnover of 5-hydroxytryptamine (5-HT) [40], another mediator of anaphylaxis and modulator of mood. Mast cell 5-HT, together with histamine released following intestinal anaphylaxis, can stimulate mesenteric

afferents via 5-HT₃ and histamine H₁ (not H₂ or H₃) receptors. Information regarding intestinal immune status can therefore be rapidly relayed to the CNS, and may play a critical role in neural reflexes and behavioural responses [41,42].

Conclusions and possible implications for therapy and policy

The prescribed dose of ranitidine was the maximum recommended daily dose for the drug. Patients referred for gastroscopy are advised to stop taking medications that interfere with gastric acid production; this includes proton pump inhibitors and H₂ receptor antagonists. Advice varies as to when medication should be interrupted and usually recommends cessation one or two weeks before the procedure. There is no recommendation to taper the dose of H₂ antagonists leading to stoppage.

Gradual reduction in dose, leading to stoppage, may or may not have been sufficient to avoid or reduce symptoms associated with excess histamine, or enhanced histamine sensitivity, in this patient. As described above, rebound hyperacidity following abrupt cessation of H₂ antagonists is well-documented. Outstanding questions relate to whether the reaction reported here occurred as a consequence of the prior high dose and duration of ranitidine treatment; the abruptness of cessation; the patient's disorder of mast cell activation (and hEDS); or a combination of some or all of these factors. It is proposed that further investigation of widespread histaminergic symptoms in relation to cessation of H₂ antagonists may be of benefit, and in particular amongst this population who may be at increased risk.

Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [43], and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [44].

References

1. Aouam K, Bouida W, Fredj NB, Chaabane A, Boubaker H, Boukef R *et al.* Severe ranitidine-induced anaphylaxis: a case report and literature review. *J Clin Pharm Ther.* 2012;**37**(4):494-496
2. Parsons ME, Ganellin CR. Histamine and its receptors. *Br J Pharmacol.* 2006;**147**(Suppl 1):S127–S135
3. Malfait F, *et al.* The 2017 international classification of the Ehlers–Danlos syndromes. *Am J Med Genet C.* 2017;**175**(1):8–26
4. Zarate N, Farmer AD, Grahame R, Mohammed SD, Knowles CH, Scott SM *et al.* Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link? *Neurogastroenterol Motil.* 2010;**22**(3):232-e78
5. Fikree A, Ghelimsky G, Collins H, Kovacic K, Aziz Q. Gastrointestinal involvement in the Ehlers-Danlos syndrome. *Am J Med Genet C Semin Med Genet.* 2017;**175**(1):181-187
6. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. *J Allergy Clin Immunol.* 2010;**126**:1099-1104
7. Valent P. Mast cell activation syndromes: definition and classification. *Allergy.* 2013;**68**:417-424
8. Afrin LB, Molderings GJ. A concise, practical guide to diagnostic assessment for mast cell activation disease. *World J Hematol.* 2014;**3**(1):1-17
9. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease – a guide to diagnosis and therapeutic options. *Ann Med.* 2016;**48**(3):190-210
10. Lin RY, Lin Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee H-S, *et al.* Histamine and tryptase levels in patients with acute allergic reactions: an emergency department–based study. *J Allergy Clin Immunol.* 2000;**106**(1):65-71
11. Akin C. Mast cell activation syndromes. *J Allergy Clin Immunol.* 2017;**140**(2):349–355

12. Cheung I, Vadas P. A New Disease Cluster: Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome *J Allergy Clin Immunol. suppl.* 2015;**S 135**(2): AB65
13. Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS *et al.* International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. *Pharmacol Rev.* 2015;**67**:601-655
14. Milligan, G. Constitutive activity and inverse agonists of G protein-coupled receptors: A current perspective. *Mol Pharmacol.*2003; **64**, 1271-1276.
15. Leurs R, Church MK, Taglialatela M. H₁-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. *Clin Exp Allergy.* 2002;**32**:489-498
16. Mahdy AM, Webster NR. Histamine and antihistamines. *Anaesthesia and Intensive Care Medicine.* 2011;**12**(7):324-329
17. Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van De Vrede Y *et al.* Inverse agonism of histamine H₂ antagonist accounts for upregulation of spontaneously active histamine H₂ receptors. *Proceedings of the National Academy of Sciences USA.* 1996;**93**:6802-6807
18. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H₂ receptor antagonists for urticaria (review) Cochrane Collaboration 2012
19. Kemp SF, Lockey RF. Anaphylaxis: A review of causes and mechanisms. *J Allergy Clin Immunol.* 2002;**110**(3):341-348
20. Makabe-Kobayashi Y, Hori Y, Adachi T, Ishigaki-Suzuki S, Kikuchi Y, Kagaya Y *et al.* The control effect of histamine on body temperature and respiratory function in IgE-dependent systemic anaphylaxis. *J Allergy Clin Immunol.* 2002;**110**(2):298–303
21. Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. *Allergy.* 2002;**57**:287-296

22. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. *J Gastroenterol Hepatol*. 2010;**25** (2):252-258
23. Joint Formulary Committee, 2017. *British National Formulary 73*. London: BMJ Group & Pharmaceutical Press
24. Parolaro D, Patrini G, Massi P, Mainardi P, Giagnoni G, Sala M *et al*. Histamine as a central modulator of rat intestinal transit. *J Pharmacol Exp Ther*. April 1989;**249**(1):324-328
25. Herwig A, Ivanova EA, Lydon H, Barrett S, Steinlechner S, Loudon AS. Histamine H₃ receptor and orexin A expression during daily torpor in the djungarian hamster (*Phodopus sungorus*). *J Neuroendocrinol*. 2007;**19**(12):1001-1007
26. Wood JD. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. *Gut*. 2006;**55**(4):445-447
27. Worm M, Edenharter G, Rueff F, Scherer K, Pfohler C, Mahler V *et al*. Symptom profile and risk factors of anaphylaxis in Central Europe. *Allergy*. 2012;**67**:691-698
28. Fullarton GM, McLauchlan G, Macdonald A, Crean GP, McColl KE. Rebound nocturnal hypersecretion after four weeks treatment with an H₂ receptor antagonist. *Gut*. 1989;**30**:449-454
29. Fullarton GM, Macdonald AM, McColl KE. Rebound hypersecretion after H₂ antagonist withdrawal – a comparative study with nizatidine, ranitidine and famotidine. *Aliment Pharmacol Ther*. 1991;**5**(4):391-398
30. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H *et al*. High constitutive activity of native H₃ receptors regulates histamine neurons in brain. *Nature* **408** | 14 DECEMBER 2000:860-864
31. Jones B, Howden DW, Burget DW, Silletti C, Hunt H. Alteration of H₂ receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H₂ receptor antagonist. *Gut*. 1988;**29**:890-893

32. Osawa S, Kajimura M, Yamamoto S, Ibuma M, Mochizuki C, Iwasaki H *et al.* Alteration of intracellular histamine H₂ receptor cycling precedes antagonist-induced upregulation. *Am J Physiol Gastrointest Liver Physiol.* 2005;**289**(5):G880-889
33. Nwokolo CU, Smith JTL, Sawyerr AM, Pounder RE. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H₂ receptor blockade. *Gut.* 1991;**32**:1455-1460
34. Monczor F, Fernandez N. Current knowledge and perspectives on histamine H₁ and H₂ receptor pharmacology: functional selectivity, receptor crosstalk and repositioning of classic histaminergic ligands. *Mol Pharmacol.* 2016;**90**:640-648
35. Alonso N, Fernandez N, Notocovich C, Monczor F, Simaan M, Baldi A *et al.* Cross-desensitization and cointernalization of H₁ and H₂ histamine receptors reveal new insights into histamine signal integration. *Mol Pharmacol.* 2013;**83**:1087-1098
36. Wingren U, Enerbäck L. Turnover of histamine in mucosal and connective tissue mast cells of the rat. *Agents and Actions.* 1984;**14**(3-4):358-360
37. Peterson J, Raithel M, Schwelberger HG. Characterisation of functional polymorphisms of the human diamine oxidase gene. *Inflamm Res.* 2005;**54**(1):S58-9
38. Lorenz W, Thon K, Barth H, Neugebauer E, Reimann HJ, Kusche J. Metabolism and function of gastric histamine in health and disease. *J Clin Gastroenterol.* 1983;**5**(1):37-56
39. Moss J, Fahmy NR, Sunder N, Beaven MA. Hormonal and hemodynamic profile of an anaphylactic reaction in man. *Circulation* 1981; **63**:210-213
40. Skrzydło-Radomańska B, Pokora J, Kleinrok Z, Radwam P. The effect of stimulation and blocking of histamine H₂ receptors on the turnover of the serotonin in different parts of the alimentary tract and the brain of the rat. *Agents and Actions.* 1985;**16**(3-4):183-86
41. Kreis ME, Haupt W, Kirkup AJ, Grundy D. Histamine sensitivity of mesenteric afferent nerves in the rat jejunum. *Am J Physiol.* 1998;**275**(4 Pt 1):G675-80.

- 389 42. Jiang W, Kreis ME, Eastwood C, Kirkup AJ, Humphrey PP, Grundy D. 5-HT (3) and histamine H
390 (1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats.
391 *Gastroenterology*. 2000;**119**(5):1267-75.
- 392 43. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S *et al*. The IUPHAR/BPS
393 Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to
394 IMMUNOPHARMACOLOGY. *Nucl Acid Res*. 2018;**46**:D1091-106.
- 395 44. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA *et al*. The
396 Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. *Br J*
397 *Pharmacol*. 2017;**174**:S17–S129.